Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: The role of cabazitaxel in the continuum of care

European Urology

Volumn 62, Issue 6, 2012, Pages 1201-1204

  Heidenreich, Axel ^a   Pfister, David ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; DOCETAXEL; MITOXANTRONE; PREDNISONE;

ABDOMINAL PAIN; ANEMIA; ASTHENIA; BACKACHE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEMATURIA; HUMAN; LETTER; LEUKOPENIA; MEDICAL DECISION MAKING; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CONTINUITY OF PATIENT CARE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84868525030     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.048     Document Type: Letter

References (19)

1. C.J. Paller, and E.S. Antonarakis Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer Drug Des Devel Ther 5 2011 117 124
2. J.S. De Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
3. Kirby RS, Patel MI. Management of castrate resistant disease. In: Fast facts: prostate cancer, ed. 7. Oxford, UK: Health Press Limited; 2010.
4. J.S. De Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
5. Zytiga [prescribing information]. Horsham, PA: Janssen Biotech; 2012.
6. D. Pouessel, S. Oudard, and G. Gravis Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France Bull Cancer 99 2012 731 741
7. Heidenreich A, Albers P, Bokemeyer C, et al. Results of a compassionate-use programme in Germany with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen [abstract 128]. Presented at: European Association of Urology annual congress; February 24-28, 2012; Paris, France.
8. D. Azria, C. Massard, and D. Tosi An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): predictive parameters of response [abstract 149] J Clin Oncol 30 Suppl 5 2012
9. Y. Loriot, C. Massard, and L. Albiges Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity [abstract 213] J Clin Oncol 30 Suppl 5 2012
10. D. Mukherji, C.J. Pezaro, and D. Bianchini Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel [abstract 17] J Clin Oncol 30 Suppl 5 2012
11. J.S. De Bono, S. Oudard, and M. Ozguroglu A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) [abstract 4526] J Clin Oncol 29 Suppl 2011
12. M.L. Zhu, C.M. Horbinski, and M. Garzotto Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Res 70 2010 7992 8002
13. J. Richards, A.C. Lim, and C.W. Hay Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 72 2012 2176 2182
14. Mezynski J, Pezar C, Bianchini D, et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. In press.
15. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
16. A.O. Sartor, S. Oudard, and M. Ozguroglu Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial [abstract 4525] J Clin Oncol. 29 Suppl 2011
17. C.J. Ryan, M.R. Smith, and J.S. de Bono Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract LBA4518] J Clin Oncol 30 15S 2012
18. S. Oudard, G. Kramer, and L. Creppy Management of metastatic castration-resistant prostate cancer (mCRPC) after an initial good response to first-line docetaxel (D): a retrospective study on 270 patients (pts) [abstract 7049] Eur J Cancer 47 Suppl 1 2011
19. D.J. Pfister, D. Porres, C. Piper, T.K. Merseburger, and A. Heidenreich Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy [abstract 243] J Clin Oncol 30 Suppl 5 2012